JP2013536234A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536234A5 JP2013536234A5 JP2013526073A JP2013526073A JP2013536234A5 JP 2013536234 A5 JP2013536234 A5 JP 2013536234A5 JP 2013526073 A JP2013526073 A JP 2013526073A JP 2013526073 A JP2013526073 A JP 2013526073A JP 2013536234 A5 JP2013536234 A5 JP 2013536234A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutical composition
- compound
- phenyl
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 4-dihydroxyborylphenyl Chemical group 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000004122 cyclic group Chemical group 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims 4
- 229910052796 boron Inorganic materials 0.000 claims 4
- 150000002148 esters Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 230000033115 angiogenesis Effects 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 201000002364 leukopenia Diseases 0.000 claims 3
- 231100001022 leukopenia Toxicity 0.000 claims 3
- 208000004235 neutropenia Diseases 0.000 claims 3
- 230000009385 viral infection Effects 0.000 claims 3
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010020751 Hypersensitivity Diseases 0.000 claims 2
- 206010021143 Hypoxia Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 208000026935 allergic disease Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 230000008733 trauma Effects 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000000668 Chronic Pancreatitis Diseases 0.000 claims 1
- 206010009137 Chronic sinusitis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- 206010055665 Corneal neovascularisation Diseases 0.000 claims 1
- 206010011224 Cough Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 208000000059 Dyspnea Diseases 0.000 claims 1
- 206010013975 Dyspnoeas Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 206010015943 Eye inflammation Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000005232 Glossitis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 208000037357 HIV infectious disease Diseases 0.000 claims 1
- 206010019728 Hepatitis alcoholic Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 206010020591 Hypercapnia Diseases 0.000 claims 1
- 206010058490 Hyperoxia Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 206010024453 Ligament sprain Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000034486 Multi-organ failure Diseases 0.000 claims 1
- 206010051606 Necrotising colitis Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000001388 Opportunistic Infections Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010033647 Pancreatitis acute Diseases 0.000 claims 1
- 206010033649 Pancreatitis chronic Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000003251 Pruritus Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000037656 Respiratory Sounds Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 208000000924 Right ventricular hypertrophy Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000010040 Sprains and Strains Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047924 Wheezing Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 201000003229 acute pancreatitis Diseases 0.000 claims 1
- 208000002353 alcoholic hepatitis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 201000009267 bronchiectasis Diseases 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 206010006475 bronchopulmonary dysplasia Diseases 0.000 claims 1
- 208000034526 bruise Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 230000006020 chronic inflammation Effects 0.000 claims 1
- 208000027157 chronic rhinosinusitis Diseases 0.000 claims 1
- 201000000159 corneal neovascularization Diseases 0.000 claims 1
- 239000013078 crystal Substances 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 206010014599 encephalitis Diseases 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 210000003714 granulocyte Anatomy 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 1
- 230000000222 hyperoxic effect Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 230000007954 hypoxia Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000004792 malaria Diseases 0.000 claims 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 208000004995 necrotizing enterocolitis Diseases 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 230000036407 pain Effects 0.000 claims 1
- 201000006195 perinatal necrotizing enterocolitis Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 230000002980 postoperative effect Effects 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 208000023504 respiratory system disease Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 125000001424 substituent group Chemical group 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000006413 ring segment Chemical group 0.000 description 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000534944 Thia Species 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 125000005382 boronyl group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 125000004438 haloalkoxy group Chemical group 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000003396 thiol group Chemical class [H]S* 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37622410P | 2010-08-23 | 2010-08-23 | |
| US61/376,224 | 2010-08-23 | ||
| PCT/US2011/048668 WO2012027289A1 (en) | 2010-08-23 | 2011-08-22 | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016077977A Division JP2016164177A (ja) | 2010-08-23 | 2016-04-08 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2018222400A Division JP2019069946A (ja) | 2010-08-23 | 2018-11-28 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536234A JP2013536234A (ja) | 2013-09-19 |
| JP2013536234A5 true JP2013536234A5 (https=) | 2019-01-24 |
| JP6486002B2 JP6486002B2 (ja) | 2019-03-20 |
Family
ID=45594546
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013526073A Active JP6486002B2 (ja) | 2010-08-23 | 2011-08-22 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2016077977A Withdrawn JP2016164177A (ja) | 2010-08-23 | 2016-04-08 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2018222400A Withdrawn JP2019069946A (ja) | 2010-08-23 | 2018-11-28 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016077977A Withdrawn JP2016164177A (ja) | 2010-08-23 | 2016-04-08 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
| JP2018222400A Withdrawn JP2019069946A (ja) | 2010-08-23 | 2018-11-28 | Ｃｘｃｒ２モジュレーターとしてのアミノピリジンカルボキサミドおよびアミノピリミジンカルボキサミド |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US8779149B2 (https=) |
| EP (1) | EP2608672B1 (https=) |
| JP (3) | JP6486002B2 (https=) |
| AU (1) | AU2011293612B2 (https=) |
| CA (1) | CA2811990C (https=) |
| WO (1) | WO2012027289A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8748623B2 (en) | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
| CA2811990C (en) * | 2010-08-23 | 2023-03-21 | Dean Y. Maeda | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
| WO2014205127A2 (en) | 2013-06-18 | 2014-12-24 | New York University | Cellular factors involved in the cytotoxicity of staphylococcus aureus leukocidins: novel therapeutic targets |
| EP3027627B1 (en) * | 2013-08-02 | 2018-01-31 | Syntrix Biosystems Inc. | 2-[5-[n-(4-fluorophenyl)carbamoyl]pyrimidin-2-ylsulfanylmethyl]-4-(trifluoromethoxy)phenyl]boronic acid |
| US10046002B2 (en) | 2013-08-02 | 2018-08-14 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| US8969365B2 (en) | 2013-08-02 | 2015-03-03 | Syntrix Biosystems, Inc. | Thiopyrimidinecarboxamides as CXCR1/2 modulators |
| US10561676B2 (en) | 2013-08-02 | 2020-02-18 | Syntrix Biosystems Inc. | Method for treating cancer using dual antagonists of CXCR1 and CXCR2 |
| WO2017070589A1 (en) * | 2015-10-22 | 2017-04-27 | Duke University | Methods and compositions for the diagnosis and treatment of central nervous system autoimmune diseases |
| CN109152780B (zh) * | 2016-03-11 | 2021-10-01 | 阿迪亚生命科学公司 | 用于治疗结晶性关节病症的cxcr-2抑制剂 |
| WO2018071687A1 (en) * | 2016-10-13 | 2018-04-19 | The Regents Of The University Of California | Methods of treating pruritis |
| US10660909B2 (en) | 2016-11-17 | 2020-05-26 | Syntrix Biosystems Inc. | Method for treating cancer using chemokine antagonists |
| WO2021163683A1 (en) | 2020-02-14 | 2021-08-19 | President And Fellows Of Harvard College | Inhibitors of nicotinamide n-methyltransferase, compositions and uses thereof |
| WO2024218236A1 (en) | 2023-04-18 | 2024-10-24 | Centre National De La Recherche Scientifique | 3,5-diaminotriazole derivatives and uses thereof for treating ocular diseases |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE817911C (de) | 1947-12-16 | 1951-10-22 | Chem Fab Tempelhof Preuss & Te | Verfahren zur Darstellung von in 6-Stellung basisch substituierten Pyridin-3-carbonsaeureamiden |
| US4139623A (en) | 1974-05-14 | 1979-02-13 | C-G Corp. | Cyclic-substituted derivatives of 1-amino-2-propanol |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US4973597A (en) | 1989-06-30 | 1990-11-27 | Eli Lilly And Company | Anticonvulsant agents |
| US5475120A (en) | 1990-11-02 | 1995-12-12 | University Of Florida | Method for the isolation and purification of taxol and its natural analogues |
| US5194635A (en) | 1991-03-18 | 1993-03-16 | Virginia Tech Intellectual Properties, Inc. | Rearranged taxol compounds and method of using in testing of in vivo activity |
| FR2684103B1 (fr) | 1991-11-22 | 1994-09-02 | Centre Nat Rech Scient | Nouveaux composes a structure guanidique et composition pharmaceutique les contenant. |
| US5488116A (en) | 1992-03-30 | 1996-01-30 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol and analogues thereof |
| US5416225A (en) | 1992-03-30 | 1995-05-16 | Sloan-Kettering Institute For Cancer Research | Total synthesis of taxol |
| JPH07505887A (ja) | 1992-04-17 | 1995-06-29 | アボツト・ラボラトリーズ | タキソール誘導体 |
| JPH07506369A (ja) * | 1992-04-29 | 1995-07-13 | エス・アール・アイ・インターナシヨナル | 炎症を処置するためのデアザアミノプテリン |
| US5440057A (en) | 1993-08-20 | 1995-08-08 | The Scripps Research Institute | Access to taxol analogs |
| US5461169A (en) | 1992-06-23 | 1995-10-24 | The Scripps Research Institute | Total synthesis of taxol and taxol analogs |
| WO1994005282A1 (en) | 1992-09-04 | 1994-03-17 | The Scripps Research Institute | Water soluble taxol derivatives |
| US5478854A (en) | 1992-10-01 | 1995-12-26 | Bristol-Myers Squibb Company | Deoxy taxols |
| US5411984A (en) | 1992-10-16 | 1995-05-02 | Virginia Tech Intellectual Properties, Inc. | Water soluble analogs and prodrugs of taxol |
| WO1994013827A1 (en) | 1992-12-07 | 1994-06-23 | Michigan State University | PROCESS FOR THE ISOLATION AND PURIFICATION OF TAXOL AND TAXANES FROM TAXUS spp |
| US5468769A (en) | 1993-07-15 | 1995-11-21 | Abbott Laboratories | Paclitaxel derivatives |
| FR2707642B1 (fr) | 1993-07-16 | 1995-10-13 | Electricite De France | Dérivés de polyéthers et d'hétérocycles pentacycliques, leurs polymères et leurs applications, notamment à la complexation d'ions métalliques. |
| US5405972A (en) | 1993-07-20 | 1995-04-11 | Florida State University | Synthetic process for the preparation of taxol and other tricyclic and tetracyclic taxanes |
| US5565478A (en) | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| GB9405347D0 (en) * | 1994-03-18 | 1994-05-04 | Agrevo Uk Ltd | Fungicides |
| US5508447A (en) | 1994-05-24 | 1996-04-16 | Board Of Regents, The University Of Texas System | Short synthetic route to taxol and taxol derivatives |
| US5489589A (en) | 1994-12-07 | 1996-02-06 | Bristol-Myers Squibb Company | Amino acid derivatives of paclitaxel |
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| CA2332957A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
| WO2001021615A1 (fr) * | 1999-09-17 | 2001-03-29 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivés de benzimidazole |
| SE9904652D0 (sv) | 1999-12-17 | 1999-12-17 | Astra Pharma Prod | Novel Compounds |
| AU2001231143A1 (en) | 2000-01-27 | 2001-08-07 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| EP1293503A4 (en) | 2000-05-19 | 2008-04-02 | Astellas Pharma Inc | Triazole derivatives |
| US7141590B2 (en) * | 2000-12-29 | 2006-11-28 | Ucb Sa | Pharmaceutical uses and synthesis of nicotinanilide-N-oxides |
| WO2002083111A2 (en) | 2001-04-16 | 2002-10-24 | Tanabe Seiyaku Co., Ltd. | Imidazole, thiazole and oxazole derivatives and their use for the manufacture of a medicament for the treatment and/or prevention of pollakiuria or urinary incontinence |
| EP1431232B1 (en) * | 2001-06-29 | 2012-11-07 | Mitsubishi Denki Kabushiki Kaisha | Elevator hoist and elevator device |
| US6777432B1 (en) | 2001-09-04 | 2004-08-17 | Darwin Molecular Corporation | Pharmaceutical uses and synthesis of nicotinamides |
| EP1429765A2 (en) * | 2001-09-14 | 2004-06-23 | Methylgene, Inc. | Inhibitors of histone deacetylase |
| US6521395B1 (en) | 2002-01-30 | 2003-02-18 | Eastman Kodak Company | Infrared couplers for incorporating and recovering metadata |
| US7176310B1 (en) | 2002-04-09 | 2007-02-13 | Ucb Sa | Pyrimidinecarboxamide derivatives and their use as anti-inflammatory agents |
| US20040110802A1 (en) | 2002-08-23 | 2004-06-10 | Atli Thorarensen | Antibacterial benzoic acid derivatives |
| US7482355B2 (en) * | 2002-08-24 | 2009-01-27 | Astrazeneca Ab | Pyrimidine derivatives as modulators of chemokine receptor activity |
| US20040116479A1 (en) * | 2002-10-04 | 2004-06-17 | Fortuna Haviv | Method of inhibiting angiogenesis |
| US20040192728A1 (en) | 2003-02-03 | 2004-09-30 | Ellen Codd | Quinoline-derived amide modulators of vanilloid VR1 receptor |
| US7459460B2 (en) * | 2003-05-28 | 2008-12-02 | Bristol-Myers Squibb Company | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators |
| US20060063930A1 (en) * | 2004-08-20 | 2006-03-23 | Agoston Gregory E | Compositions and methods comprising proteinase activated receptor antagonists |
| DK1789390T3 (da) | 2004-09-02 | 2012-02-27 | Genentech Inc | Pyridyl-inhibitorer af hedgehog-signalering |
| US7091202B2 (en) * | 2004-09-15 | 2006-08-15 | Bristol-Myers Squibb Company | 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators |
| JP2006117568A (ja) | 2004-10-20 | 2006-05-11 | Mitsubishi Pharma Corp | チオフェン環を有する新規アミド誘導体及びその医薬としての用途 |
| WO2006070806A1 (ja) | 2004-12-28 | 2006-07-06 | Taiho Pharmaceutical Co., Ltd. | 新規ベンゾイミダゾール化合物及び該化合物を含有する医薬組成物 |
| WO2006121719A2 (en) | 2005-05-06 | 2006-11-16 | Boehringer Ingelheim International, Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| US20070078172A1 (en) | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| EP1910290A2 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | Gpcr agonists |
| US8138209B2 (en) | 2005-07-13 | 2012-03-20 | Jenrin Discovery, Inc. | Substituted picolinamides as MAO-B inhibitors useful for treating obesity |
| AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
| WO2007028082A1 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-substituted- 2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AU2006329007A1 (en) * | 2005-12-20 | 2007-06-28 | Novartis Ag | Nicotinic acid derivatives as modulators of metabotropic glutamate receptors |
| WO2007098352A2 (en) | 2006-02-16 | 2007-08-30 | Boehringer Ingelheim International Gmbh | Substituted pyridineamide compounds useful as soluble epoxide hydrolase inhibitors |
| TW200813035A (en) | 2006-06-19 | 2008-03-16 | Astrazeneca Ab | Novel heteroaryl substituted benzoxazoles |
| EP2049124A4 (en) | 2006-07-20 | 2010-02-10 | Merck & Co Inc | PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER |
| JP5470653B2 (ja) * | 2006-10-26 | 2014-04-16 | アムジエン・インコーポレーテツド | カルシウム受容体調節剤 |
| CN102838532A (zh) | 2006-11-24 | 2012-12-26 | Ac免疫有限公司 | 用于治疗与淀粉样物质或淀粉样蛋白有关的疾病的吡唑胺和噻唑胺衍生物 |
| WO2008073461A2 (en) | 2006-12-11 | 2008-06-19 | Wyeth | Ion channel modulators |
| JP2010512418A (ja) * | 2006-12-11 | 2010-04-22 | ワイス エルエルシー | イオンチャネルモジュレータ−としてのカルボキサミド誘導体 |
| WO2008123469A1 (ja) * | 2007-03-30 | 2008-10-16 | Japan Tobacco Inc. | ６員環アミド化合物およびその用途 |
| SA08290245B1 (ar) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم |
| US8263585B2 (en) * | 2007-05-04 | 2012-09-11 | Novartis Ag | Organic compounds |
| CA2695071A1 (en) * | 2007-08-02 | 2009-02-05 | F. Hoffmann-La Roche Ag | The use of benzamide derivatives for the treatment of cns disorders |
| AU2008285795A1 (en) | 2007-08-03 | 2009-02-12 | F. Hoffmann-La Roche Ag | Pyridinecarboxamide and benzamide derivatives as TAAR1 ligands |
| WO2009037503A2 (en) | 2007-09-18 | 2009-03-26 | Astrazeneca Ab | New combination - 012 for the treatment of respiratory diseases |
| WO2009053269A1 (en) | 2007-10-23 | 2009-04-30 | F. Hoffmann-La Roche Ag | Novel kinase inhibitors |
| KR101237576B1 (ko) * | 2007-12-04 | 2013-03-04 | 에프. 호프만-라 로슈 아게 | 아이속사졸로-피리딘 유도체 |
| KR20110036044A (ko) * | 2008-07-18 | 2011-04-06 | 다케다 파머수티컬 컴패니 리미티드 | 벤즈아제핀 유도체들 및 히스타민 ｈ3 길항제로서 이들의 용도 |
| MX2011002825A (es) | 2008-09-18 | 2011-04-05 | Astellas Pharma Inc | Compuestos heterociclicos de carboxamida. |
| US8748623B2 (en) * | 2009-02-17 | 2014-06-10 | Syntrix Biosystems, Inc. | Pyridinecarboxamides as CXCR2 modulators |
| EP2236505A1 (de) * | 2009-04-03 | 2010-10-06 | Bayer CropScience AG | Acylierte Aminopyridine und - pyridazine als Insektizide |
| BRPI1013766A2 (pt) * | 2009-05-07 | 2016-04-05 | Hoffmann La Roche | "derivados de isoxazol-piridina como moduladores de gaba" |
| PL2470173T3 (pl) * | 2009-08-25 | 2016-11-30 | Leczenie skojarzone nanocząstkowymi kompozycjami taksanu i inhibitorów hedgehog | |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| CA2811990C (en) | 2010-08-23 | 2023-03-21 | Dean Y. Maeda | Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators |
-
2011
- 2011-08-22 CA CA2811990A patent/CA2811990C/en active Active
- 2011-08-22 EP EP11820471.8A patent/EP2608672B1/en active Active
- 2011-08-22 AU AU2011293612A patent/AU2011293612B2/en active Active
- 2011-08-22 US US13/215,014 patent/US8779149B2/en not_active Ceased
- 2011-08-22 JP JP2013526073A patent/JP6486002B2/ja active Active
- 2011-08-22 WO PCT/US2011/048668 patent/WO2012027289A1/en not_active Ceased
-
2014
- 2014-05-20 US US14/283,118 patent/US8993541B2/en not_active Ceased
-
2016
- 2016-04-08 JP JP2016077977A patent/JP2016164177A/ja not_active Withdrawn
- 2016-07-14 US US15/210,803 patent/USRE47740E1/en active Active
-
2017
- 2017-03-24 US US15/469,395 patent/USRE48547E1/en active Active
-
2018
- 2018-11-28 JP JP2018222400A patent/JP2019069946A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536234A5 (https=) | ||
| DK2706062T3 (en) | Hitherto unknown cephalosporine derivative and pharmaceutical composition thereof | |
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| JP5852562B2 (ja) | 新規なセフェム誘導体 | |
| JP2012505891A5 (https=) | ||
| RU2016150486A (ru) | Ингибиторы бета-лактамазы | |
| JP2016514719A5 (https=) | ||
| JP2018515581A5 (https=) | ||
| JP2016506369A5 (https=) | ||
| JP2005534684A5 (https=) | ||
| JP2012522793A5 (https=) | ||
| JP2012530137A5 (https=) | ||
| TW201020259A (en) | Catechol-containing cephalosporins | |
| CH615190A5 (https=) | ||
| JP2017529389A5 (https=) | ||
| JP2005505595A5 (https=) | ||
| JP2016501185A5 (https=) | ||
| JP2016532669A5 (https=) | ||
| JP2016529306A5 (https=) | ||
| JP2017538767A5 (https=) | ||
| JP2007537272A5 (https=) | ||
| RU2015137976A (ru) | Ингибиторы лейкотриен а4-гидролазы | |
| JP2013540712A5 (https=) | ||
| RU2015137975A (ru) | Ингибиторы лейкотриен-a4-гидролазы | |
| JP2008509955A5 (https=) |